文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV-1耐药基因型超深度测序与一线治疗6个月病毒学应答

HIV-1 resistance genotyping by ultra-deep sequencing and 6-month virological response to first-line treatment.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

研究使用Sentosa超深度测序平台对237例未治疗HIV-1感染者进行聚合酶耐药基因型检测,采用3%和20%两个突变检测阈值。6个月病毒学应答率为87%,多因素分析显示应答与基线病毒载量和至少对一种蛋白酶抑制剂耐药相关。作者认为该平台适用于一线治疗患者的耐药检测,但需进一步研究其在治疗管理中的应用。

要点

  • 3%阈值下ANRS算法检出29%样本对至少一种药物耐药,Stanford算法为16%。
  • 20%阈值下ANRS算法检出24%耐药,Stanford算法为13%。
  • 6个月病毒学应答率87%,与基线病毒载量及至少一种蛋白酶抑制剂耐药相关。

核心结论

  • Vela超深度测序平台适用于一线抗逆转录病毒治疗患者的耐药检测。
  • 作者指出需进一步研究超深度测序在治疗管理中的应用。

研究设计与样本

  • 对237份连续未治疗个体样本使用Sentosa超深度测序平台进行HIV-1聚合酶耐药基因型检测,采用3%和20%两个突变检测阈值。
  • 病毒学应答定义为治疗6个月后血浆HIV-1病毒载量<50 copies/mL。

主要发现

  • 3%阈值下,ANRS算法检出29%样本对至少一种抗逆转录病毒药物耐药,Stanford算法为16%。
  • 3%阈值下,ANRS算法显示14.3%样本对至少一种蛋白酶抑制剂敏感性降低,12.7%对一种逆转录酶抑制剂,5.1%对一种整合酶抑制剂。
  • 20%阈值下,ANRS算法检出24%样本耐药,Stanford算法为13%。
  • 6个月病毒学应答率为87%,在58%接受整合酶抑制剂为基础治疗、16%接受蛋白酶抑制剂为基础治疗和9%接受非核苷类逆转录酶抑制剂为基础治疗的患者中相似。
  • 多因素分析显示病毒学应答与基线HIV病毒载量及3%和20%阈值下ANRS算法检出的至少一种蛋白酶抑制剂耐药相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需进一步研究超深度测序在治疗管理中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the routine use of the Sentosa ultra-deep sequencing (UDS) system for HIV-1 polymerase resistance genotyping in treatment-naïve individuals and to analyse the virological response (VR) to first-line antiretroviral treatment. METHODS: HIV drug resistance was determined on 237 consecutive samples from treatment-naïve individuals using the Sentosa UDS platform with two mutation detection thresholds (3% and 20%). VR was defined as a plasma HIV-1 virus load <50 copies/mL after 6 months of treatment. RESULTS: Resistance to at least one antiretroviral drug with a mutation threshold of 3% was identified in 29% and 16% of samples according to ANRS and Stanford algorithms, respectively. The ANRS algorithm also revealed reduced susceptibility to at least one protease inhibitor (PI) in 14.3% of samples, to one reverse transcriptase inhibitor in 12.7%, and to one integrase inhibitor (INSTI) in 5.1%. For a mutation threshold of 20%, resistance was identified in 24% and 13% of samples according to ANRS and Stanford algorithms, respectively. The 6 months VR was 87% and was similar in the 58% of patients given INSTI-based treatment, in the 16% given PI-based treatment and in the 9% given NNRTI-based treatment. Multivariate analysis indicated that the VR was correlated with the baseline HIV virus load and resistance to at least one PI at both 3% and 20% mutation detection thresholds (ANRS algorithm). CONCLUSIONS: The Vela UDS platform is appropriate for determining antiretroviral resistance in patients on a first-line antiretroviral treatment. Further studies are needed on the use of UDS for therapeutic management.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Raymond S, Jeanne N, Nicot F, et al. HIV-1 resistance genotyping by ultra-deep sequencing and 6-month virological response to first-line treatment. J Antimicrob Chemother. 2023. PMID: 36449383. doi:10.1093/jac/dkac391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。